Article Text

Download PDFPDF
High-Dose Chemotherapy for Adult-Type Ovarian Granulosa Cell Tumors: A Retrospective Study of the European Society for Blood and Marrow Transplantation
  1. Ugo De Giorgi, MD, PhD,
  2. Emmanuelle Nicolas-Virelizier, MD,
  3. Manuela Badoglio, PhD,
  4. Peter Bader, MD,
  5. Sandrine Richard, MD,
  6. Johan Maertens, MD,
  7. Francesco Lanza, MD and
  8. Marco Bregni, MD
  1. * Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Meldola, Italy;
  2. Centre Leon Berard, Lyon; and
  3. EBMT Paris Office, Paris, France;
  4. § Universitatsklinikum Frankfurt, Frankfurt, Germany;
  5. Hopital Tenon, Paris, France;
  6. University Hospital Gasthuisberg, Leuven, Belgium; and
  7. # Hematology Unit, Ravenna Hospital, Ravenna; and
  8. ** Ospedale di Busto Arsizio, Varese, Italy.
  1. Address correspondence and reprint requests to Ugo De Giorgi, MD, PhD, Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS, Via Maroncelli 40, 47014 Meldola, Italy. E-mail: ugo.degiorgi{at}


Objectives A few small retrospective series reported results with salvage chemotherapy for malignant ovarian adult-type granulosa cell tumors (GCTs), whereas no data are available on high-dose chemotherapy (HDC) with hematopoietic progenitor cell support (HSCS) in these patients. The aim of this study was to analyze the available data of HDC for adult-type GCTs.

Methods We conducted a retrospective analysis of ovarian cancer treated with salvage HDC registered with the European Society for Blood and Marrow Transplantation.

Results Of 203 adult female patients with a diagnosis of nonepithelial ovarian cancer treated with salvage HDC with HSCS and registered with the European Society for Blood and Marrow Transplantation, 4 (2%) patients were affected by GCTs. All 4 patients had ovarian adult-type GCTs that relapsed/progressed after first-line chemotherapy. The conditioning regimens included a platinum agent in all 4 patients. Bone marrow recovery was promptly achieved; neither treatment-related deaths or life-threatening toxicities occurred. At a median follow-up of 8.5 months, all patients reported a progressive disease. The patient who underwent multicycle HDC enjoyed a long-term remission of 84 months before progression and is the only one alive after 94+ months.

Conclusions We showed for the first time a case with long-lasting response to salvage multicycle HDC and HSCS in adult-type GCTs.

  • Adult-type ovarian granulosa cell tumors
  • Ovarian cancer
  • Salvage chemotherapy
  • High-dose chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.